Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Voorthuizen, T. van"'
Autor:
Rosmalen, B.V. van, Furumaya, A., Klompenhouwer, A.J., Tushuizen, M.E., Braat, A.E., Reinten, R.J., Ligthart, M.A.P., Haring, M.P.D., Meijer, V.E. de, Voorthuizen, T. van, Takkenberg, R.B., Dejong, C.H.C., Man, R.A. de, IJzermans, J.N.M., Doukas, M., Gulik, T.M. van, Verheij, J., Dutch Benign Liver Tumor Grp, PALGA Grp
Publikováno v:
Liver International
Liver international, 41(10), 2474-2484. Wiley-Blackwell
Liver International, 41(10), 2474-2484. Wiley
Liver International, 41(10), 2474-2484. Wiley-Blackwell Publishing Ltd
Liver International, 41(10), 2474-2484. WILEY
Liver international, 41(10), 2474-2484. Wiley-Blackwell
Liver International, 41(10), 2474-2484. Wiley
Liver International, 41(10), 2474-2484. Wiley-Blackwell Publishing Ltd
Liver International, 41(10), 2474-2484. WILEY
BACKGROUND & AIMS: Hepatocellular adenomas (HCA) rarely occur in males, and if so, are frequently associated with malignant transformation. Guidelines are based on small numbers of patients and advise resection of HCA in male patients, irrespective o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8631d704b2ae8f5eca8dc90acc72a8a
https://doi.org/10.1111/liv.14989
https://doi.org/10.1111/liv.14989
Autor:
Badrising, S.K., Noort, V. van der, Eertwegh, A.J.M. van den, Hamberg, P., Oort, I.M. van, Berg, H.P. van den, M. los, Aarts, M.J.B., Coenen, J.L.L.M., Gelderblom, H., Jong, I.J. de, Kerver, E.D., Vrijaldenhoven, S., Voorthuizen, T. van, Warmerdam, F., Haanen, J.B., Bergman, A.M., DUOS
Publikováno v:
Prostate, 76, 32-40
Prostate, 76(1), 32-40
Prostate, 76, 1, pp. 32-40
Prostate, 76(1), 32-40
Prostate, 76, 1, pp. 32-40
Item does not contain fulltext BACKGROUND: Abiraterone Acetate (AA) and Enzalutamide (Enz) are effective hormonal treatments in mCRPC patients. Retrospective studies suggested clinical cross-resistance between Enz and AA. However, 12.8-39.1% of patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::500c8329724dfff859cbcf83b6f2611d
http://hdl.handle.net/2066/171273
http://hdl.handle.net/2066/171273
Autor:
Badrising, S.K., Noort, V. van der, Hamberg, P., Coenen, J.L.L.M., Aarts, M.J., Oort, I.M. van, Eertwegh, A.J.M. van den, M. los, Berg, H.P. van den, Gelderblom, H., Vrijaldenhoven, S., Kerver, E.D., Voorthuizen, T. van, Jong, I.J. de, Haanen, J.B., Bergman, A.M., Dutch Uro-Oncol Study Grp DUOS
Publikováno v:
Oncology : journal of clinical and experimental cancer research, 91(5), 267-273. KARGER
Oncology, 91(5), 267-273. S. Karger AG
Badrising, S K, van der Noort, V, Hamberg, P, Coenen, J L L M, Aarts, M J, van Oort, I M, van den Eertwegh, A J M, Los, M, van den Berg, H P, Gelderblom, H, Vrijaldenhoven, S, Kerver, E D, van Voorthuizen, T, de Jong, I J, Haanen, J B, Bergman, A M & Dutch Uro-Oncology Study Group (DUOS) 2016, ' Enzalutamide as a Fourth-or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer ', Oncology, vol. 91, no. 5, pp. 267-273 . https://doi.org/10.1159/000448219
Oncology (Basel: 1948), 91, 5, pp. 267-273
Oncology (Basel: 1948), 91, 267-273
Oncology, 91(5), 267-273. Karger
Oncology, 91(5), 267-273
Oncology, 91(5), 267-273. S. Karger AG
Badrising, S K, van der Noort, V, Hamberg, P, Coenen, J L L M, Aarts, M J, van Oort, I M, van den Eertwegh, A J M, Los, M, van den Berg, H P, Gelderblom, H, Vrijaldenhoven, S, Kerver, E D, van Voorthuizen, T, de Jong, I J, Haanen, J B, Bergman, A M & Dutch Uro-Oncology Study Group (DUOS) 2016, ' Enzalutamide as a Fourth-or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer ', Oncology, vol. 91, no. 5, pp. 267-273 . https://doi.org/10.1159/000448219
Oncology (Basel: 1948), 91, 5, pp. 267-273
Oncology (Basel: 1948), 91, 267-273
Oncology, 91(5), 267-273. Karger
Oncology, 91(5), 267-273
Objective: To evaluate the efficacy of enzalutamide (Enz) as fourth- or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC), by analyzing a retrospective cohort of heavily pretreated patients. Methods: We evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dca8b6195ac05ce8160daf10d82ca2d8
https://doi.org/10.1159/000448219
https://doi.org/10.1159/000448219